mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
Emerg Microbes Infect
; 11(1): 1550-1553, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-35604772
ABSTRACT
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Limits:
Humans
Language:
En
Journal:
Emerg Microbes Infect
Year:
2022
Document type:
Article